Kurt Von Emster

Kurt joined Abingworth in January 2015 bringing over 25 years of experience in life science investment. He began his career as a biotechnology and healthcare analyst in 1990, and then was promoted to Vice President and Portfolio Manager at Franklin Templeton. Kurt then became a General Partner at MPM Capital in 2000. In 2009, he co-founded venBio, a US healthcare investment firm and most recently was a Partner in the San Francisco office. He holds board positions at CymaBay, Jasper Therapeutics, Orbus Therapeutics, SFJ Pharmaceuticals, Tizona Therapeutics, Trishula Therapeutics, Vaxcyte and Vera Therapeutics. He was formerly on boards at Aurinia, CRISPR Therapeutics, Cytos, Kesios, Facet and Somaxon. Kurt holds a Bachelor of Science in Business and Economics and is a Chartered Financial Analyst.